Struthers Richard Scott's Form 4 filing
Crinetics Pharmaceuticals, Inc. (CRNX) · filed Apr 8, 2024
- Accession no.
- 0000950170-24-042681
- Filed
- Apr 8, 2024
- Trade date
- Apr 4, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $2.01M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Struthers Richard ScottCIK 0001746298 | Director, Officer (President & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 4, 2024 | Common Stock | MOption exerciseAcquired | +40,951 | $9.28 | +$380,025.28 | 278,786 | Direct | |
| Apr 4, 2024 | Common Stock | SSaleDisposed | −40,951 | $49.17F2 | −$2,013,560.67 | 237,835 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 4, 2024 | Common Stock | MOption exerciseDisposed | −40,951 | $0.00 | $0 | 123,790 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The common stock was sold by the reporting person in open market transactions on the transaction date, with a weighted average sales price of $49.17 per share. The range of sales prices on the transaction date was $48.95 to $49.56 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
Referenced by the price of 1 transaction in Table I.